Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Check-Cap (NASDAQ:CHEKFree Report) in a research report report published on Monday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 0.9 %

Shares of CHEK stock opened at $0.80 on Monday. Check-Cap has a 12-month low of $0.76 and a 12-month high of $3.45. The business’s 50 day moving average is $1.19 and its two-hundred day moving average is $1.73. The company has a market capitalization of $4.68 million, a P/E ratio of -0.27 and a beta of 0.39.

About Check-Cap

(Get Free Report)

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.

Featured Articles

Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.